Pegbio
China - HangzhouBiotechnology
Focus: Pegbio is a Chinese biotechnology company focused on chronic disease treatments, particularly in oncology. Founded in 2008 and based in Hangzhou, the company operates in the competitive biotech landscape.
Profile data last refreshed 22h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Pegbio
AI assessmentNot HiringNo open roles listed right now. Follow Pegbio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
glucokinase activator
Type2 Diabetes MellitusClinical Trials (1)
NCT03973515Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus
Phase 1Help build intelligence for Pegbio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.